

1 **Concussion-associated gene variant *COMT* rs4680 is associated with elite rugby athlete**
2 **status**

3 **Authors;** Mark R. Antrobus ^{1, 2,*}, Jon Brazier ^{1, 3}, Peter Callus ¹, Adam J. Herbert ⁴, Georgina K.
4 Stebbings ¹, Stephen H. Day ⁵, Liam P. Kilduff ⁶, Mark A. Bennett ⁶, Robert M. Erskine ^{7, 11},
5 Stuart M. Raleigh ⁸, Malcolm Collins ⁹, Yannis P. Pitsiladis ¹⁰, Shane M. Heffernan ⁶, and Alun
6 G. Williams ^{1, 11}

7 **Abstract word count: 245**

8 **Manuscript word count: 2999**

9 **Affiliations**

10 ¹ Sports Genomics Laboratory, Department of Sport and Exercise Sciences, Manchester
11 Metropolitan University, Manchester M1 5GD, UK

12 ² Sport and Exercise Science, University of Northampton, Northampton NN1 5PH, UK

13 ³ Department of Psychology and Sports Sciences, University of Hertfordshire, Hatfield AL10
14 9AB, UK

15 ⁴School of Health Sciences, Birmingham City University, Birmingham, UK

16 ⁵ Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1
17 1LY, UK

18 ⁶ Applied Sports Science Technology and Medicine Research Centre (A-STEM), Faculty of
19 Science and Engineering, Swansea University, Swansea SA1 8EN, UK

20 ⁷ Research Institute for Sport & Exercise Sciences, Liverpool John Moores University,
21 Liverpool L3 3AF, UK

22 ⁸School of Health Sciences, Coventry University, Coventry, UK

23 ⁹ Division of Exercise Science and Sports Medicine, Department of Human Biology,
24 University of Cape Town, Cape Town, South Africa

25 ¹⁰ FIMS Reference Collaborating Centre of Sports Medicine for Anti-Doping Research,
26 University of Brighton, Brighton, UK

27 ¹¹ Institute of Sport, Exercise and Health, University College London, London WC1E 6BT, UK

28

29 *Correspondence: mark.antrobus@northampton.ac.uk

30 **Abstract**

31 **Objective:**

32 Concussions are common match injuries in elite rugby and reports exist of reduced cognitive
33 function and long-term health consequences that can interrupt or end a playing career and
34 produce continued ill health. The aim of this study was to investigate the association between
35 elite rugby status and eight concussion-associated risk polymorphisms. We hypothesized that
36 concussion-associated risk genotypes and alleles would be underrepresented in elite rugby
37 athletes compared to non-athletes.

38 **Design:**

39 A case-control genetic association study.

40 **Setting:**

41 Institutional (university).

42 **Participants:**

43 Elite Caucasian male rugby athletes (n = 668, mean (standard deviation) height 1.85 (0.07) m,
44 mass 102 (12) kg, age 29 (7) yr) and 1015 non-athlete Caucasian men and women (48% men).

45 **Interventions:**

46 Genotype was the independent variable, obtained via PCR of genomic DNA using TaqMan
47 probes.

48 **Main Outcome Measure:**

49 Elite athlete status, with groups compared using χ^2 and odds ratio.

50 **Results:**

51 The *COMT* rs4680 Met/Met (AA) genotype, Met allele possession and Met allele frequency
52 were lower in rugby athletes (24.8%, 74.6% and 49.7%, respectively) than non-athletes
53 (30.2%, 77.6%, and 54.0%; $P < 0.05$). The Val/Val (GG) genotype was more common in elite

54 rugby athletes than non-athletes (odds ratio 1.39, 95% confidence interval 1.04-1.86). No
55 other polymorphism was associated with elite athlete status.

56

57 **Conclusions:**

58 Elite rugby athlete status is associated with *COMT* rs4680 genotype that, acting
59 pleiotropically, could affect stress resilience and behavioral traits during competition,
60 concussion risk and/or recovery from concussion. Consequently, assessing *COMT* rs4680
61 genotype might aid future individualized management of concussion risk amongst athletes.

62 **Key words;** rugby, genetics, concussion, brain, polymorphism, behavior

63 **Introduction**

64 Rugby is a full contact high velocity collision-based team sport comprised of two differing
65 codes, Rugby League (RL) and Rugby Union (RU). Both are characterized by multiple high-
66 intensity collisions (RL 24-47, RU 24-89 contact events per match) [1,2]. Contact events are
67 responsible for the prevalence of concussion in both codes of rugby [3–5]. Sport-related
68 concussion has been defined as a form of traumatic brain injury (TBI) induced by
69 biomechanical forces [6]. In the 2017-18 season of the English RU Premiership (the top tier of
70 competition in England) there was a reported incidence of ~18 concussions per 1000 match
71 hours (~0.7 concussion per match) [5]. In elite RL, concussion incidence ranges from ~15-28
72 concussions per 1000 player match hours [3,7].

73 Potential short- and long-term neurodegenerative consequences associated with concussion
74 include increased injury risk, migraines, sleep dysfunction, anxiety, cognitive impairment,
75 second impact syndrome, chronic post-concussion syndrome and forms of dementia [6,8–
76 16]. These consequences impact on continuance of an athletic career, causing temporary
77 suspension of play, early retirement and potential neuropathological consequences.

78 Concussion has a polygenic component due to the actions and interactions of multiple genes
79 [17]. Two common C/T single nucleotide polymorphisms (SNPs) at residues 112 (rs429358)
80 and 158 (rs7412) of the *apolipoprotein E (APOE)* gene have been associated with forms of TBI
81 [18,19] and in combination are termed $\epsilon 2/\epsilon 3/\epsilon 4$. *APOE* $\epsilon 4$ allele could be responsible for up

82 to 64% of the ‘hazardous influence’ of TBI [18] and athletes who possess the $\epsilon 4$ allele suffered
83 from prolonged physical (Cohen’s $d = 0.87$) and cognitive ($d = 0.60$) symptomatic responses
84 to concussion [20]. A promoter region SNP of *APOE* (rs405509) has been associated with
85 quantitative impacts on APOE levels in brain tissue [21]. Carriers of the T allele (rs405509) had
86 a 3-8-fold greater risk of experiencing repeated concussions [22,23] and TT genotype carriers
87 experienced lower Glasgow Outcome Scale scores post-TBI [24]. In contrast, Abrahams et al.
88 [25] reported TT genotype (rs405509) was associated with a 45% reduced risk of concussion
89 and the T allele was associated with a rapid recovery (< 1 week) post-concussion in RU players.
90 *Microtubule associated protein tau (MAPT)* TT genotype (rs10445337) has been weakly
91 associated with a greater risk of repeated concussion [23,26]. Mutations in *MAPT* accelerate
92 aggregation of markers of neurotoxic hyperphosphorylated tau in response to repetitive
93 concussions by 20-60% in animal-based studies and are associated with neurodegenerative
94 diseases in humans [27,28]. The *nitric oxide synthase 3 (NOS3)* -786T/C polymorphism
95 (rs2070744) has been associated with promoter region activity, reduced NO synthesis and
96 cerebral vasospasm [29]. Approximately 20-35% lower cerebral blood flow has been reported
97 in patients with severe TBI who carry the C allele [30].

98 The T allele (rs1800497) of the *ankyrin repeat and kinase domain-containing 1 (ANKK1)* gene
99 has been associated with a 30-40% reduction in the expression of D2 receptors within the
100 ventral striatum [31,32]. Post-TBI T allele carriers perform worse in measures of learning,
101 working memory and response latencies [33–35]. A polymorphism (rs6265) of the *brain*
102 *derived neurotrophic factor (BDNF)* gene has been associated with neurocognitive
103 performance post-concussion; G allele carriers performed approximately 2-6 times better in
104 memory, executive function, attention and overall cognitive performance, both acutely and
105 6 months post-concussion compared to A allele carriers [36]. In addition, AA homozygotes
106 appear to be at higher risk of sustaining a concussion than GG homozygotes (~17% of AA
107 homozygotes suffered a concussion compared to ~4% of AG/GG) [37]. The G (Val) to A (Met)
108 missense variation at codon 158 (rs4680) in the *catechol-O-methyltransferase (COMT)* gene
109 appears to have multiple, pleiotropic effects. It is associated with behavioral traits and
110 executive function [38], with Lipsky et al. [39] reporting that Val homozygotes performed 40%
111 poorer on tests of executive function than Met homozygotes post-TBI. Significantly, Met-
112 carrying RU players are reportedly ~3-fold more likely to have a history of concussion [40].

113 However, in addition, the *COMT* warrior/worrier theory describes the Val allele as
114 advantageous for stress resilience (warrior) and the Met allele advantageous for cognitive
115 function (worrier) [41,42]. Indeed, mixed martial arts professional fighter status is associated
116 with Val/Val genotype [43], potentially due to better performance in threatening
117 environments [44]. Thus, *COMT* could also influence rugby player behaviors, including those
118 that affect risk of concussion.

119 Given the biological and clinical associations with the polymorphisms introduced here,
120 possession of the risk alleles might limit an individual's ability to withstand exposure to the
121 environment of competitive rugby due to an elevated risk of repeated concussions and
122 greater risk of delayed recovery and consequent neurological impairment. Such individuals
123 would be more likely than their peers to miss training, selection and competitive events
124 important for career progression. Indeed, Heffernan et al. [45] previously reported an
125 association between injury risk-associated *COL5A1* (rs12722 and rs3196378) polymorphisms
126 and elite rugby status based on the same premise regarding career progression.

127 The primary aim of this study, therefore, was to investigate whether genotype frequency of
128 suspected concussion-associated polymorphisms differed between elite rugby athletes and a
129 non-athlete control population, and between RU playing positions. Based on published
130 associations of the polymorphisms with concussion risk and poorer outcome following brain
131 injury, and the interruption to competitive careers that could result, it was hypothesized that
132 the concussion-associated risk genotypes and alleles would be underrepresented in elite
133 rugby athletes compared to non-athletes. In other words, it was hypothesized that rugby
134 athletes would have greater genetic resistance to concussion than non-athletes, because that
135 would have facilitated their prolonged participation in a high-risk environment.

136 **Methods**

137 *Participants*

138 As part of the ongoing RugbyGene project [46], a total of 1683 individuals were recruited and
139 gave written informed consent to participate in the present study. An *a priori* calculation for
140 80% power to detect a small effect size (w) of 0.1 required >785 participants and 0.12 required
141 >546 participants. The total sample comprised 668 Caucasian elite male rugby athletes (mean
142 (standard deviation) height 1.85 (0.07) m, mass 102 (12) kg, age 29 (7) yr) including 62.9%

143 British, 13.8% South African, 10.8% Irish, 8.9% Italian, and 3.6% of other nationalities, and
144 1015 Caucasian non-athletes (48% male, height 1.71 (0.11) m, mass 73 (13) kg, age 38 (22) yr)
145 including 91.8% British, 6.7% South African, 1.5% other nationalities. Male and female non-
146 athletes were suitable for genotype frequency comparison with the general population
147 because the gene variants analyzed in this study are not sex-linked, and genotype frequencies
148 did not differ between our male and female non-athletes. Athletes were considered elite if
149 they had competed regularly (>5 matches) since 1995 in the highest professional league in
150 the UK, Ireland or South Africa for RU, or the highest professional league in the UK for RL.
151 49.1% of the RU athletes had competed at international level for a “high performance union”
152 (Regulation 16, <http://www.worldrugby.org>) and 42% of RL athletes had competed
153 internationally. As the majority of athletes competed in RU, they were also divided into
154 forwards and backs for comparison. Ethical approval was granted by the ethics committees
155 of Manchester Metropolitan University, University of Glasgow, University of Cape Town and
156 University of Northampton, and all experimental procedures complied with the Declaration
157 of Helsinki [47].

158 *Procedures*

159 *Sample collection.* Procedures were consistent with those described previously [45,48,49].
160 Blood (70.4% of all samples), buccal swabs (15.4%) or saliva (14.2%) samples were obtained
161 (dependent upon environment, location and participant preference). Blood was drawn from
162 a superficial forearm vein into EDTA tubes, saliva samples were collected into Oragene DNA
163 OG-500 tubes (DNA Genotek, Ottawa, Ontario, Canada), and sterile buccal swabs (Whatman
164 OmniSwab, Springfield Mill, UK) were rubbed against the buccal mucosa of the cheek for ~30
165 s.

166 *DNA isolation and genotyping.* DNA isolation and genotyping were performed in the
167 Manchester, Glasgow and Cape Town laboratories. The majority of samples were processed
168 in the Manchester laboratory. There are some differences between protocols, summarized
169 below.

170 In Manchester and Glasgow, DNA isolation was performed with the QIAamp DNA Blood Mini
171 kit and spin column protocol (Qiagen, West Sussex, UK). Briefly, 200 μ L of whole blood was
172 lysed and incubated, the DNA washed, and the eluate stored at 4°C. In Cape Town, using a

173 different protocol [50], samples were lysed and centrifuged, the DNA washed, and samples
174 stored at -20°C. DNA isolated in Cape Town was genotyped in Glasgow.

175 Genotyping for eight polymorphisms (see *Primers and probes*) was performed using two
176 protocols. Protocol one: Approximately 40% of samples were genotyped using a StepOnePlus
177 (Applied Biosystems, Paisley, UK) as previously described [48] with variations to
178 thermocycling conditions depending on reagents used. Protocol two: Approximately 60% of
179 samples were genotyped by combining 2 μ L GTXpress Master Mix (2X) (Applied Biosystems),
180 0.2 μ L 20X Fast GT Sample Loading Reagent (Fluidigm, Cambridge, UK), 0.2 μ L H₂O and 1.6 μ L
181 of purified DNA. Furthermore, 1.78 μ L assay (20X) (Applied Biosystems), 1.78 μ L 2X Assay
182 Loading Reagent (Fluidigm) and 0.18 μ L ROX reference dye (Invitrogen, Paisley, UK) were
183 combined. An integrated fluid circuit controller RX (Fluidigm) mixed samples and assays using
184 a Load Mix (166x) script. PCR was performed using a real-time FC1 Cyclor (Fluidigm) GT
185 192X24 Fast v1 protocol. The 192X24 microchip plate was placed into the EP1 Reader
186 (Fluidigm) for end-point analysis using Fluidigm SNP genotyping analysis software. Duplicates
187 of all samples were in 100% agreement for both protocols.

188 **Genotyping assays**

189 For *ANKK1* (rs1800497), *APOE* (rs429358, rs7412 and rs405509), *BDNF-AS* (rs6265), *COMT*
190 (rs4680), *MAPT* (rs10445337) and *NOS3* (rs2070744), the appropriate TaqMan assays were
191 utilised (Applied Biosystems). *APOE* ϵ 2/ ϵ 3/ ϵ 4 data were derived from rs429358 and rs7412
192 [51]. The TaqMan assay context sequence for each polymorphism, with VIC/FAM highlighted
193 in **bold** and concussion-associated risk alleles underlined (although for some the prior
194 evidence of risk is controversial), were: *ANKK1* (rs1800497) TGGTC[**A/G**]AGGCA, *APOE*
195 (rs429358) ACGTG[**C/T**]GCGGC, *APOE* (rs7412) AGAAG[**C/T**]GCCTG, *APOE* (rs405509)
196 GTCTG[**G/T**]ATTAC, *BDNF-AS* (rs6265) TATCA[**C/T**]GTGTT, *COMT* (rs4680)
197 CTGGC[**A/G**]TGAAG, *MAPT* (rs10445337) TCACT[**C/T**]CCCGA, *NOS3* (rs2070744)
198 CTGGC[**C/T**]GGCTGA.

199 **Data Analysis**

200 SPSS for Windows version 26 (SPSS, Chicago, IL) software was used. Height and body mass
201 were compared between athletes and non-athletes using independent t-tests. Pearson's χ^2

202 tests compared genotype and allele frequencies between athletes and non-athletes and
 203 between positional subgroups. Twenty-four comparisons per SNP (18 for *APOE* $\epsilon 2/\epsilon 3/\epsilon 4$)
 204 were subjected to Benjamini-Hochberg corrections [BH;52] to control false discovery rate and
 205 corrected probability values are reported. Odds ratios (OR) were calculated to estimate effect
 206 size. Alpha was set at 0.05.

207

208 Results

209 Genotype frequencies were in Hardy-Weinberg equilibrium for all polymorphisms in the non-
 210 athlete and athlete groups. Athletes (all male) were taller and heavier ($P < 0.05$) than the male
 211 non-athletes.

212 For *COMT* rs4680, the AA (Met/Met) genotype, proportion of A allele carriers and A allele
 213 were underrepresented in all athletes (24.8%, 74.6% and 49.7%, respectively) and RU athletes
 214 (24.3%, 73.1%, and 48.7%) compared with non-athletes (30.2%, 77.6%, and 54.0%, Table 1
 215 and Fig. 1, $P \leq 0.05$). The GG (Val/Val) genotype was more common in all rugby athletes than
 216 non-athletes (OR = 1.39, 95% confidence interval (CI) = 1.04-1.86), and more common in RU
 217 athletes than non-athletes (OR = 1.49, 95% CI = 1.10-2.03). The AA genotype was
 218 underrepresented in the subgroup of RU backs compared with the non-athletes (21.1% versus
 219 30.3%, Table 1, $P \leq 0.05$), with the GG genotype more common in RU backs (OR = 1.62, 95%
 220 CI = 1.07-2.48). However, there was no difference in genotype frequency between RU backs
 221 and forwards ($P = 0.49$).

222 **Table 1.** Genotype and allele distribution of non-athletes and athletes, including athletes separated by code (RL
 223 and RU) and into positional groups for RU. Data are genotype/allele count followed by percentage in
 224 parentheses.

Polymorphism	Genotype	All Rugby Athletes	RL Athletes	RU Athletes	RU Forwards	RU Backs	Non-athletes
<i>ANKK1</i> rs1800497	GG	417 (65.2)	59 (58.4)	358 (66.5)	208 (66.1)	150 (66.1)	475 (65.2)
	GA	198 (31.0)	37 (36.6)	161 (29.9)	99 (31.4)	64 (28.2)	223 (30.6)
	AA	24 (3.8)	5 (5.0)	19 (3.5)	8 (2.5)	13 (5.7)	31 (4.2)
	Total	639	101	538	315	227	729
	G allele	1032 (80.8)	155 (76.7)	877 (81.5)	515 (81.7)	364 (80.2)	1173 (80.5)

A allele	258 (20.2)	47 (23.3)	199 (18.5)	115 (18.3)	90 (19.8)	285 (19.5)
G allele carriers	615 (96.2)	96 (95.1)	519 (96.5)	307 (97.5)	214 (94.3)	698 (95.7)
A allele carriers	222 (34.7)	42 (41.6)	180 (33.5)	107 (34.0)	77 (33.9)	254 (34.8)

**APOE
rs405509**

GG	163 (25.8)	23 (23.0)	140 (26.3)	75 (24.4)	66 (28.8)	191 (26.2)
GT	308 (48.7)	51 (51.0)	257 (48.3)	154 (50.2)	105 (45.9)	344 (47.3)
TT	161 (25.5)	26 (26.0)	135 (25.4)	78 (25.4)	58 (25.3)	193 (26.5)
Total	632	100	532	307	229	728
G allele	634 (50.2)	97 (48.5)	537 (50.5)	304 (49.5)	237 (51.7)	726 (49.9)
T allele	630 (49.8)	103 (51.5)	527 (49.5)	310 (50.5)	221 (48.3)	730 (50.1)
G allele carriers	471 (74.5)	74 (74.0)	397 (74.6)	229 (74.6)	171 (74.7)	535 (73.5)
T allele carriers	469 (74.2)	77 (77.0)	392 (73.7)	232 (75.6)	163 (71.2)	537 (73.8)

**APOE
ε2/ε3/ε4**

ε2/ε2	1 (0.2)	0 (0.0)	1 (0.2)	1 (0.3)	0 (0.0)	4 (0.6)
ε2/ε3	74 (11.2)	14 (13.7)	60 (10.8)	32 (10.0)	28 (11.8)	88 (12.7)
ε2/ε4	11 (1.7)	1 (1.0)	10 (1.8)	7 (2.2)	3 (1.3)	19 (2.7)
ε3/ε3	393 (59.7)	51 (50)	342 (61.5)	199 (62.0)	146 (61.3)	404 (58.5)
ε3/ε4	159 (24.2)	32 (31.4)	127 (22.8)	73 (22.7)	54 (22.7)	159 (23.0)
ε4/ε4	20 (3.0)	4 (3.9)	16 (2.9)	9 (2.8)	7 (2.9)	17 (2.5)
Total	658	102	556	321	238	691
ε4 allele carriers	190 (28.9)	37 (36.3)	153 (27.5)	89 (27.7)	64 (26.9)	195 (28.2)
Non- ε4 allele carriers	468 (71.1)	65 (63.7)	403 (72.5)	232 (72.3)	174 (73.1)	496 (71.8)

**BDNF-AS
rs6265**

GG	432 (67.5)	74 (73.3)	358 (66.4)	206 (65.4)	154 (67.6)	530 (66.3)
GA	185 (28.9)	23 (22.7)	162 (30.1)	98 (31.1)	66 (28.9)	241 (30.1)
AA	23 (3.6)	4 (4.0)	19 (3.5)	11 (3.5)	8 (3.5)	29 (3.6)
Total	640	101	539	315	228	800
G allele	1049 (82.0)	171 (84.7)	878 (81.4)	510 (81.0)	374 (82.0)	1301 (81.3)
A allele	231 (18.0)	31 (15.3)	200 (18.6)	120 (19.0)	82 (18.0)	299 (18.7)
G allele carriers	617 (96.4)	97 (96.0)	520 (96.5)	304 (96.5)	220 (96.5)	771 (96.4)
A allele carriers	208 (32.5)	27 (26.7)	181 (33.6)	109 (34.6)	74 (32.5)	270 (33.8)

COMT rs4680

GG	164 (25.4)	18 (17.8)	146 (26.8)	86 (27.0)	60 (26.5)	178 (22.4)
GA	321 (49.8)	55 (54.5)	266 (48.9)	149 (46.9)	116 (51.3)	377 (47.4)
AA	160 (24.8)*	28 (27.7)	132 (24.3)*	83 (26.1)	50 (22.1)*	241 (30.2)
Total	645	101	544	318	226	796
G allele	649 (50.3)	91 (45.0)	558 (51.3)	321 (50.5)	236 (52.2)	733 (46.0)

A allele	641 (49.7)*	111 (55.0)	530 (48.7)*	315 (49.5)	216 (47.8)*	859 (54.0)
G allele carriers	485 (75.2)	73 (72.3)	412 (75.7)	235 (73.9)	176 (77.9)	555 (69.7)
A allele carriers	478 (74.6)	83 (82.2)	398 (73.1)	232 (73.0)	166 (73.5)	618 (77.6)

**MAPT
rs10445337**


TT	384 (59.6)	54 (53.5)	330 (60.8)	201 (63.8)	133 (57.4)	465 (63.9)
TC	230 (35.7)	40 (39.6)	190 (35.0)	102 (32.4)	88 (37.9)	229 (31.5)
CC	30 (4.7)	7 (6.9)	23 (4.2)	12 (3.8)	11 (4.7)	34 (4.7)
Total	644	101	543	315	232	728
T allele	998 (77.5)	148 (73.3)	850 (78.3)	504 (80.0)	354 (76.3)	1159 (79.6)
C allele	290 (22.5)	54 (26.7)	236 (21.7)	126 (20.0)	110 (23.7)	297 (20.4)
T allele carriers	614 (95.3)	94 (93.1)	520 (95.8)	303 (96.2)	221 (95.3)	694 (95.3)
C allele carriers	260 (40.4)	47 (46.5)	213 (39.2)	114 (36.2)	99 (42.7)	263 (36.1)

**NOS3
rs2070744**

TT	239 (37.6)	36 (35.6)	203 (37.9)	115 (37.0)	91 (39.9)	282 (38.7)
CT	303 (47.6)	50 (49.5)	251 (46.9)	145 (46.6)	106 (46.5)	323 (44.3)
CC	94 (14.8)	15 (14.9)	81 (15.2)	51 (16.4)	31 (13.6)	124 (17.0)
Total	636	101	535	311	228	729
T allele	781 (61.4)	122 (60.4)	657 (61.4)	375 (60.3)	288 (63.2)	887 (60.8)
C allele	491 (38.6)	80 (39.6)	413 (38.6)	247 (39.7)	168 (36.8)	571 (39.2)
T allele carriers	542 (85.2)	86 (85.1)	454 (84.9)	260 (83.6)	197 (86.4)	605 (83.0)
C allele carriers	397 (62.4)	65 (64.4)	332 (62.1)	196 (63.0)	137 (60.1)	447 (61.3)

225 The genotype and allele carrier data represent the additive, dominant and recessive models, respectively.
 226 Asterisks (*) indicate lower frequency than non-athletes ($P \leq 0.05$).

227



228

229 **Figure 1.** Allele frequency of *COMT* rs4680 for non-athletes and athlete groups. G allele = black, A allele = grey.
 230 Asterisks (*) indicate G (Val) allele more common and A (Met) allele less common in athletes than non-athletes
 231 ($P \leq 0.05$). RU, rugby union; RL, rugby league.

232

233 There were no differences in *APOE* $\epsilon 2/\epsilon 3/\epsilon 4$ genotype or $\epsilon 4$ allele possession frequency when
 234 comparing all ($P = 0.19$, $P = 0.71$), RU ($P = 0.28$, $P = 0.71$), RU forwards ($P = 0.62$, $P = 0.85$) and
 235 RU backs ($P = 0.62$, $P = 0.65$) with non-athletes (Table 1). Furthermore, no *APOE* $\epsilon 2/\epsilon 3/\epsilon 4$
 236 genotype frequency or $\epsilon 4$ allele possession differences were observed between RU backs and
 237 forwards ($P = 0.87$, $P = 0.83$, respectively). There were no differences in *APOE* rs405509
 238 genotype or allele frequency when comparing all groups of athletes to non-athletes (Table 1).
 239 In addition, no *APOE* rs405509 differences in genotype or allele frequency were observed
 240 between RU backs and forwards.

241 Similarly, there were no differences in genotype or allele frequency when comparing all
242 athletes with non-athletes for all other polymorphisms (*ANKK1* rs1800497, *BDNF-AS* rs6265,
243 *MAPT* rs10445337 and *NOS3* rs2070744) ($P > 0.05$; Table 1). Furthermore, no genotype
244 frequency or allele differences were observed between RU backs and forwards for all other
245 polymorphisms analyzed in this study (Table 1).

246

247 **Discussion**

248 The aim of this study was to investigate whether genotype frequency of eight suspected
249 concussion-associated polymorphisms differed between elite rugby athletes and a non-
250 athlete control population, and between RU playing positions. It was hypothesized that the
251 concussion-associated risk genotypes and alleles would be underrepresented in elite rugby
252 athletes compared to non-athletes, because of the interruption to competitive careers that
253 could result. The main finding was that *COMT* rs4680 genotype was associated with elite
254 rugby athlete status. However, the elite rugby athletes had ~1.4 times the odds of being
255 Val/Val (GG) genotype (previously associated with poorer cognitive function post-concussion)
256 than non-athletes, contradicting our original hypothesis. Nevertheless, *COMT* rs4680 has
257 pleiotropic effects as the two alleles have varying associations with history of concussion and
258 behavioral traits [40,43,44], some compatible with our observation.

259 Previously, *COMT* Val/Val (GG) homozygotes have been associated with poorer cognitive
260 function than Met/Met (AA) homozygotes. Specifically, following mild TBI non-verbal
261 cognitive function was affected [53] and following more severe TBI executive function was
262 affected [39]. This evidence led us to suspect that possessing the Met allele would contribute
263 to the attainment of elite status via quicker or more complete recovery following TBI after

264 the inevitable high-intensity contacts that occur during rugby. Thus, better cognitive function
265 post-concussion would facilitate rugby athletes' prolonged participation in the high
266 concussion-risk environment of competitive rugby. However, the Val/Val genotype was
267 overrepresented in elite rugby athletes (25.4%), and RU athletes separately (26.8%),
268 compared to non-athletes (22.4%) (Figure 1). *COMT* encodes an enzyme that methylates and
269 in turn deactivates catechol-based neurotransmitters such as synaptic dopamine [39].
270 Optimal cognitive function is affected by the prefrontal cortex's (PFC) sensitivity to dopamine
271 [54], which makes *COMT* a strong candidate to influence inter-individual variability in
272 cognitive function post-concussion. Chen *et al.* [55] noted Met/Met carriers had ~33%
273 decreased COMT activity (higher dopamine activity) compared to Val/Val carriers (lower
274 dopamine activity); heterozygotes had intermediate activity.

275 Furthermore, Mc Fie *et al.* [40] recently reported Met carriers in a cohort of youth and
276 professional South African RU players were ~3-fold more likely to have a history of
277 concussion. Elevated dopamine could increase impulsivity and risk taking, meaning Met allele
278 carriers could place themselves at increased risk of sustaining a concussion [56,57]. We found
279 the Met allele was underrepresented in elite rugby athletes (49.7%), RU athletes (48.7%), RU
280 forwards (49.5%) and RU backs (47.8%) compared to non-athletes (54.0%). Our findings are
281 therefore compatible with Mc Fie *et al.* [40], because lower risk of concussion via the Val allele
282 would provide less disruption to rugby training and selection, increasing the chance of long-
283 term career success. However, further replication studies are warranted to support this
284 hypothesis.

285 Professional fighters have been reported to have a higher frequency of Val/Val genotype
286 (52%) than non-athletes (20%) [43]. The higher COMT activity in the PFC of Val/Val carrying

287 professional fighters (compared to the MET carriers) is in line with the COMT warrior/worrier
288 U-shaped curve theory of excessive or insufficient dopamine in the PFC impairing cognitive
289 performance [41,42]. Previous findings indicate that Val/Val carriers performing under
290 stressful conditions would have an increased resilience to stress and be more able to cope
291 with perceived threats [41,43]. Met allele carriers have an increased reactivity to aversive
292 stimuli and relative greater cognitive performance capacity than Val carriers [41,42,58,59].
293 This greater executive function and working memory of Met allele carriers is attributed to the
294 effects of higher levels of extracellular dopamine in the PFC [41,42], although some
295 differences between sexes might also exist [60]. In addition, the Met allele has been
296 associated with experiencing anxiety and pain sensitivity characteristics unfavorable for elite
297 rugby competition in some studies [61,62] but not all [63–65].

298 For *APOE* $\epsilon 2/\epsilon 3/\epsilon 4$ there were no differences in $\epsilon 4/\epsilon 4$ genotype or $\epsilon 4$ allele frequency
299 between elite rugby athletes and non-athletes (Table 1). Previous findings indicate that $\epsilon 4$
300 allele carriers experience more severe cognitive and physical symptoms following TBI [18–
301 20], so we hypothesized that the $\epsilon 4$ allele would be underrepresented in elite rugby athletes
302 compared to non-athletes. However, the present data do not support that hypothesis, despite
303 elite rugby being an environment of high risk of concussion [3–5,7,66,67]. Nevertheless, it is
304 noteworthy that 28.9% of elite rugby athletes were $\epsilon 4$ carriers, including several of $\epsilon 4/\epsilon 4$
305 genotype (3.0% of all athletes), who may be at elevated risk of cognitive and physical
306 impairments post-concussion compared to non-carriers [18–20].

307 Similarly, we found no association between any other polymorphism examined in this study
308 and elite rugby athlete status. However, based on previous biological and clinical data
309 regarding those polymorphisms, our study confirms the existence of a considerable number

310 of athletes who appear to have a genetic predisposition for sustaining repetitive concussions
311 and/or poorer outcomes post-concussion. For example, ~20% of elite rugby athletes could be
312 at risk of poorer cognitive performance post-concussion due to possession of either the A
313 allele of *ANNK1* rs1800497 or the A allele of *BDNF* rs6265 [33–36]. In addition, 60% of elite
314 rugby athletes possess the *MAPT* rs10445337 TT genotype which could suggest a greater risk
315 of repeated concussion [23,26] and potential risk of neurodegenerative disease [27,28].
316 Similarly, 60% of elite rugby athletes could experience reduced cerebral blood flow post-
317 concussion due to possession of the *NOS3* rs20707044 C allele [29,30].

318 **Conclusion**

319 A considerable number of elite rugby athletes possess several concussion-associated risk
320 alleles that should be explored further in conjunction with concussion injury data. In addition,
321 the Val allele and Val/Val genotype of the *COMT* rs4680 polymorphism were more common
322 in elite rugby athletes than non-athletes, suggesting an advantage for attaining elite
323 competitive status. Based on this observation and prior literature, we propose that elite rugby
324 athletes possessing the Val allele of *COMT* (rs4680) could be at lower risk of experiencing
325 concussions, potentially due to greater stress resilience and reduced anxiety in threatening
326 competitive environments. However, they might also be at increased risk of poorer cognitive
327 function post-concussion. Consequently, we recommend continued careful monitoring of
328 brain injury in rugby, tight adherence to return-to-play procedures, and the development of
329 more sensitive methods for early detection of neurodegeneration, particularly in those
330 athletes potentially at higher risk.

331 **References**

332 (1) Gabbett, T. J.; Jenkins, D. G.; Abernethy, B. Physical Collisions and Injury in Professional Rugby

- 333 League Match-Play. *J. Sci. Med. Sport* **2011**, *14* (3), 210–215.
334 <https://doi.org/10.1016/j.jsams.2011.01.002>.
- 335 (2) Roberts, S. P.; Trewartha, G.; Higgitt, R. J.; El-Abd, J.; Stokes, K. A.; El-abd, J. The Physical
336 Demands of Elite English Rugby Union. *J. Sports Sci.* **2008**, *26* (8), 825–833.
337 <https://doi.org/10.1080/02640410801942122>.
- 338 (3) Gardner, A.; Iverson, G. L.; Levi, C. R.; Schofield, P. W.; Kay-Lambkin, F.; Kohler, R. M. N.;
339 Stanwell, P. A Systematic Review of Concussion in Rugby League. *Br. J. Sports Med.* **2015**, *49*
340 (8), 495–498. <https://doi.org/10.1136/bjsports-2013-093102>.
- 341 (4) Fuller, C. W.; Taylor, A.; Kemp, S. P. T.; Raftery, M. Rugby World Cup 2015: World Rugby
342 Injury Surveillance Study. *Br. J. Sports Med.* **2017**, *51* (1), 51–57.
343 <https://doi.org/10.1136/bjsports-2016-096275>.
- 344 (5) England Professional Rugby Injury Surveillance Project Steering Group. England Professional
345 Rugby Injury Surveillance Project 2017-2018 Season Report. *London, UK*. 2019, p 15.
- 346 (6) McCrory, P.; Meeuwisse, W.; Dvorak, J.; Aubry, M.; Bailes, J.; Broglio, S.; Cantu, B.; Cassidy, D.;
347 Echemendia, R. J.; Castellani, R. J.; Davis, G. A.; Ellenbogen, R.; Emery, C.; Engebretsen, L.;
348 Feddermann-Demont, N.; Giza, C. C.; Guskiewicz, K. M.; Herring, S.; Iverson, G. L.; Johnston, K.
349 M.; Kissick, J.; Kutcher, J.; Leddy, J. J.; Maddocks, D.; Makdissim M.; Manley, G.; McCrea, M.;
350 Meehan, W. P.; Nagahiro, S.; Patricios, J.; Putukian, M.; Schneider, K. J.; Sills, A.; Tator, C. H.;
351 Turner, M.; Vos, P. E. Consensus Statement on Concussion in Sport—the 5th International
352 Conference on Concussion in Sport Held in Berlin, October 2016. *Br. J. Sports Med.* **2018**, *51*,
353 838–847.
- 354 (7) Gardner, A. J.; Iverson, G. L.; Williams, W. H.; Baker, S.; Stanwell, P. A Systematic Review and
355 Meta-Analysis of Concussion in Rugby Union. *Sport. Med.* **2014**, *44* (12), 1717–1731.
356 <https://doi.org/10.1007/s40279-014-0233-3>.
- 357 (8) Cunningham, J.; Broglio, S.; Wilson, F. Influence of Playing Rugby on Long-Term Brain Health
358 Following Retirement: A Systematic Review and Narrative Synthesis. *BMJ Open Sport Exerc.*
359 *Med.* **2018**, *4* (1), e000356. <https://doi.org/10.1136/bmjsem-2018-000356>.
- 360 (9) Hume, P.; Theadom, A.; Lewis, G.; Quarrie, K.; Brown, S.; Hill, R.; Marshall, S. A Comparison of
361 Cognitive Function in Former Rugby Union Players Compared with Former Non-Contact-Sport
362 Players and the Impact of Concussion History. *Sport. Med.* **2017**, *47* (6), 1209–1220.
363 <https://doi.org/10.1007/s40279-016-0608-8>.

- 364 (10) Quintana, L. M. Second Impact Syndrome in Sports. *World Neurosurg.* **2016**, *91*, 647–649.
365 <https://doi.org/10.1016/j.wneu.2016.04.035>.
- 366 (11) Lee, Y.-K.; Hou, S.-W.; Lee, C.-C.; Hsu, C.-Y.; Huang, Y.-S.; Su, Y.-C. Increased Risk of Dementia
367 in Patients with Mild Traumatic Brain Injury: A Nationwide Cohort Study. *PLoS One* **2013**, *8*
368 (5), e62422. <https://doi.org/10.1371/journal.pone.0062422>.
- 369 (12) Cross, M.; Kemp, S.; Smith, A.; Trewartha, G.; Stokes, K. Professional Rugby Union Players
370 Have a 60% Greater Risk of Time Loss Injury after Concussion: A 2-Season Prospective Study
371 of Clinical Outcomes. *Br. J. Sports Med.* **2016**, *50* (15), 926–931.
372 <https://doi.org/10.1136/bjsports-2015-094982>.
- 373 (13) Kerr, Z. Y.; Evenson, K. R.; Rosamond, W. D.; Mihalik, J. P.; Guskiewicz, K. M.; Marshall, S. W.
374 Association between Concussion and Mental Health in Former Collegiate Athletes. *Inj.*
375 *Epidemiol.* **2014**, *1* (1), 28. <https://doi.org/10.1186/S40621-014-0028-X>.
- 376 (14) Guskiewicz, K. M.; Marshall, S. W.; Bailes, J.; McCrea, M.; Harding, H. P.; Matthews, A.;
377 Mihalik, J. R.; Cantu, R. C. Recurrent Concussion and Risk of Depression in Retired
378 Professional Football Players. *Med. Sci. Sport. Exerc.* **2007**, *39* (6), 903–909.
379 <https://doi.org/10.1249/mss.0b013e3180383da5>.
- 380 (15) Stulemeijer, M.; Andriessen, T. M.; Brauer, J. M. P.; Vos, P. E.; Van Der Werf, S. Cognitive
381 Performance after Mild Traumatic Brain Injury: The Impact of Poor Effort on Test Results and
382 Its Relation to Distress, Personality and Litigation. *Brain Inj.* **2007**, *21* (3), 309–318.
383 <https://doi.org/10.1080/02699050701209980>.
- 384 (16) Blennow, K.; de Leon, M.; Zetterberg, H. Alzheimer's Disease. *Lancet* **2006**, *368* (9533), 387–
385 403. [https://doi.org/10.1016/S0140-6736\(06\)69113-7](https://doi.org/10.1016/S0140-6736(06)69113-7).
- 386 (17) Panenka, W. J.; Gardner, A. J.; Dretsch, M. N.; Crynen, G. C.; Crawford, F. C.; Iverson, G. L.
387 Systematic Review of Genetic Risk Factors for Sustaining a Mild Traumatic Brain Injury.
388 *Journal of Neurotrauma*. Mary Ann Liebert Inc. July 1, 2017, pp 2093–2099.
389 <https://doi.org/10.1089/neu.2016.4833>.
- 390 (18) Lawrence, D. W.; Comper, P.; Hutchison, M. G.; Sharma, B. The Role of Apolipoprotein E
391 Epsilon (ϵ)-4 Allele on Outcome Following Traumatic Brain Injury: A Systematic Review. *Brain*
392 *Inj.* **2015**, *29* (9), 1018–1031. <https://doi.org/10.3109/02699052.2015.1005131>.
- 393 (19) Zhou, W.; Xu, D.; Peng, X.; Zhang, Q.; Jia, J.; Crutcher, K. A. Meta-Analysis of APOE4 Allele and
394 Outcome after Traumatic Brain Injury. *J. Neurotrauma* **2008**, *25* (4), 279–290.

- 395 <https://doi.org/10.1089/neu.2007.0489>.
- 396 (20) Merritt, V.; Arnett, P. Apolipoprotein E (APOE) E4 Allele Is Associated with Increased
397 Symptom Reporting Following Sports Concussion. *J. Int. Neuropsychol. Soc.* **2016**, *22*, 89–94.
398 <https://doi.org/10.1017/S1355617715001022>.
- 399 (21) Lambert, J.-C.; Araria-Goumidi, L.; Myllykangas, L.; Ellis, C.; Wang, J. C.; Bullido, M. J.; Harris, J.
400 M.; Artiga, M. J.; Hernandez, D.; Kwon, J. M.; Frigard, B.; Petersen, R. C.; Cumming, A. M.;
401 Pasquier, F.; Sastre, I.; Tienari, P. J.; Frank, A.; Sulkava, R.; Morris, J. C.; St Clair, D.; Mann, D.
402 M.; Wavrant-DeVrièze, F.; Ezquerra-Trabalon, M.; Amouyel, P.; Hardy, J.; Haltia, M.;
403 Valdivieso, F.; Goate, A. M.; Pérez-Tur, J.; Lendon, C. L.; Chartier-Harlin, M.-C. Contribution of
404 APOE Promoter Polymorphisms to Alzheimer’s Disease Risk. *Neurology* **2002**, *59* (1), 59–66.
405 <https://doi.org/10.1212/wnl.59.1.59>.
- 406 (22) Tierney, R.; Mansell, J.; Higgins, M.; McDevitt, J.; Toone, N.; Gaughan, J.; Mishra, A.;
407 Krynetskiy, E. Apolipoprotein E Genotype and Concussion in College Athletes. *Clin. J. Sport*
408 *Med.* **2010**, *20* (6), 464–468. <https://doi.org/10.1097/JSM.0b013e3181fc0a81>.
- 409 (23) Terrell, T.; Bostick, R.; Abramson, R.; Xie, D.; Barfield, W.; Cantu, R.; Stanek, M.; Ewing, T.
410 APOE, APOE Promoter, and Tau Genotypes and Risk for Concussion in College Athletes. *Clin. J.*
411 *Sport Med.* **2008**, *18* (1), 10–17. <https://doi.org/10.1097/JSM.0b013e31815c1d4c>.
- 412 (24) Lendon, C. L.; Harris, J. M.; Pritchard, A. L.; Nicoll, J. A. R.; Teasdale, G. M.; Murray, G. Genetic
413 Variation of the APOE Promoter and Outcome after Head Injury. *Neurology* **2003**, *61* (5), 683–
414 685. <https://doi.org/10.1212/01.wnl.0000078033.81925.80>.
- 415 (25) Abrahams, S.; Mc Fie, S.; Patricios, J.; Sutere, J.; Posthumus, M.; Septembera AV. An
416 Association between Polymorphisms within the APOE Gene and Concussion Aetiology in
417 Rugby Union Players. *J. Sci. Med. Sport* **2018**, *21* (2), 117–122.
418 <https://doi.org/10.1016/J.JSAMS.2017.06.004>.
- 419 (26) Terrell, T.; Bostick, R.; Barth, J.; McKeag, D.; Cantu, R.; Sloane, R.; Galloway, L.; Erlanger, D.;
420 Valentine, V.; Bielak, K. Genetic Polymorphisms, Concussion Risk, and Post Concussion
421 Neurocognitive Deficits in College and High School Athletes. *Br. J. Sports Med.* **2013**, *47* (5),
422 e1.25-e1. <https://doi.org/10.1136/bjsports-2012-092101.31>.
- 423 (27) Poorkaj, P.; Bird, T. D.; Wijsman, E.; Nemens, E.; Garruto, R. M.; Anderson, L.; Andreadis, A.;
424 Wiederholt, W. C.; Raskind, M.; Schellenberg, G. D. Tau Is a Candidate Gene for Chromosome
425 17 Frontotemporal Dementia. *Ann. Neurol.* **1998**, *43* (6), 815–825.

- 426 <https://doi.org/10.1002/ana.410430617>.
- 427 (28) Xu, L.; Ryu, J.; Nguyen, J. V.; Arena, J.; Rha, E.; Vranis, P.; Hitt, D.; Marsh-Armstrong, N.;
428 Koliatsos, V. E. Evidence for Accelerated Tauopathy in the Retina of Transgenic P301S Tau
429 Mice Exposed to Repetitive Mild Traumatic Brain Injury. **2015**.
430 <https://doi.org/10.1016/j.expneurol.2015.08.014>.
- 431 (29) Asif, A. R.; Oellerich, M.; Armstrong, V. W.; Hecker, M.; Cattaruzza, M. T-786C Polymorphism
432 of the Nos-3 Gene and the Endothelial Cell Response to Fluid Shear Stress - A Proteome
433 Analysis. *J. Proteome Res.* **2009**, *8* (6), 3161–3168. <https://doi.org/10.1021/pr800998k>.
- 434 (30) Robertson, C. S.; Gopinath, S. P.; Valadka, A. B.; Van, M.; Swank, P. R.; Goodman, J. C. Variants
435 of the Endothelial Nitric Oxide Gene and Cerebral Blood Flow after Severe Traumatic Brain
436 Injury. *J. Neurotrauma* **2011**, *28* (5), 727–737. <https://doi.org/10.1089/neu.2010.1476>.
- 437 (31) Ritchie, T.; Noble, E. P. Association of Seven Polymorphisms of the D2 Dopamine Receptor
438 Gene with Brain Receptor-Binding Characteristics. *Neurochem. Res.* **2003**, *28* (1), 73–82.
439 <https://doi.org/10.1023/A:1021648128758>.
- 440 (32) Thompson, J.; Thomas, N.; Singleton, A.; Piggott, M.; Lloyd, S.; Perry, E. K.; Morris, C. M.;
441 Perry, R. H.; Ferrier, I. N.; Court, J. A. D2 Dopamine Receptor Gene (DRD2) Taq 1 A
442 Polymorphism: Reduced Dopamine D2 Receptor Binding in the Human Striatum Associated
443 with the A1 Allele. *Pharmacogenetics* **1997**, *7* (6), 479–484.
444 <https://doi.org/10.1097/00008571-199712000-00006>.
- 445 (33) Yue, J. K.; Pronger, A. M.; Ferguson, A. R.; Temkin, N. R.; Sharma, S.; Rosand, J.; Sorani, M. D.;
446 McAllister, T. W.; Barber, J.; Winkler, E. A.; Burchard, E. G.; Hu, D.; Lingsma, H. F.; Cooper, S.
447 R.; Puccio, A. M.; Okonkwo, D. O.; Diaz-Arrastia, R.; Manley, G. T.; COBRIT Investigators;
448 TRACK-TBI Investigators. Association of a Common Genetic Variant within ANKK1 with Six-
449 Month Cognitive Performance after Traumatic Brain Injury. *Neurogenetics* **2015**, *16* (3), 169–
450 180. <https://doi.org/10.1007/s10048-015-0437-1>.
- 451 (34) McAllister, T. W.; Flashman, L. A.; Harker Rhodes, C.; Tyler, A. L.; Moore, J. H.; Saykin, A. J.;
452 McDonald, B. C.; Tosteson, T. D.; Tsongalis, G. J. Single Nucleotide Polymorphisms in ANKK1
453 and the Dopamine D2 Receptor Gene Affect Cognitive Outcome Shortly after Traumatic Brain
454 Injury: A Replication and Extension Study. *Brain Inj.* **2008**, *22* (9), 705–714.
455 <https://doi.org/10.1080/02699050802263019>.
- 456 (35) McAllister, T. W.; Rhodes, C. H.; Flashman, L. A.; McDonald, B. C.; Belloni, D.; Saykin, A. J.

- 457 Effect of the Dopamine D2 Receptor T Allele on Response Latency after Mild Traumatic Brain
458 Injury. *Am. J. Psychiatry* **2005**, *162* (9), 1749–1751.
459 <https://doi.org/10.1176/appi.ajp.162.9.1749>.
- 460 (36) Narayanan, V.; Veeramuthu, V.; Ahmad-Annuar, A.; Ramli, N.; Waran, V.; Chinna, K.; Bondi,
461 M. W.; Delano-Wood, L.; Ganesan, D. Missense Mutation of Brain Derived Neurotrophic
462 Factor (BDNF) Alters Neurocognitive Performance in Patients with Mild Traumatic Brain
463 Injury: A Longitudinal Study. *PLoS One* **2016**, *11* (7), e0158838.
464 <https://doi.org/10.1371/journal.pone.0158838>.
- 465 (37) Dretsch, M. N.; Williams, K.; Emmerich, T.; Crynen, G.; Ait-Ghezala, G.; Chaytow, H.; Mathura,
466 V.; Crawford, F. C.; Iverson, G. L. Brain-Derived Neurotropic Factor Polymorphisms, Traumatic
467 Stress, Mild Traumatic Brain Injury, and Combat Exposure Contribute to Postdeployment
468 Traumatic Stress. *Brain Behav.* **2016**, *6* (1), 1–12. <https://doi.org/10.1002/brb3.392>.
- 469 (38) Gallinat, J.; Bajbouj, M.; Sander, T.; Schlattmann, P.; Xu, K.; Ferro, E. F.; Goldman, D.;
470 Winterer, G. Association of the G1947A COMT (Val(108/158)Met) Gene Polymorphism with
471 Prefrontal P300 during Information Processing. *Biol. Psychiatry* **2003**, *54* (1), 40–48.
472 [https://doi.org/10.1016/s0006-3223\(02\)01973-x](https://doi.org/10.1016/s0006-3223(02)01973-x).
- 473 (39) Lipsky, R. H.; Sparling, M. B.; Ryan, L. M.; Xu, K.; Salazar, A. M.; Goldman, D.; Warden, D. L.
474 Association of COMT Val158Met Genotype with Executive Functioning Following Traumatic
475 Brain Injury. *J. Neuropsychiatry Clin. Neurosci.* **2005**, *17* (4), 465–471.
476 <https://doi.org/10.1176/jnp.17.4.465>.
- 477 (40) Mc Fie, S.; Abrahams, S.; Patricios, J.; Suter, J.; Posthumus, M.; September, A. V. The
478 Association between COMT Rs4680 and 5-HTTLPR Genotypes and Concussion History in
479 South African Rugby Union Players. *J. Sports Sci.* **2018**, *36* (8), 920–933.
480 <https://doi.org/10.1080/02640414.2017.1346274>.
- 481 (41) Goldman, D.; Oroszi, G.; Ducci, F. The Genetics of Addictions: Uncovering the Genes. *Nature*
482 *Reviews Genetics*. Nat Rev Genet July 2005, pp 521–532. <https://doi.org/10.1038/nrg1635>.
- 483 (42) Goldman-Rakic, P. S.; Muly, E. C.; Williams, G. V. D1 Receptors in Prefrontal Cells and Circuits.
484 *Brain Res. Rev.* **2000**, *31* (2–3), 295–301. [https://doi.org/10.1016/S0165-0173\(99\)00045-4](https://doi.org/10.1016/S0165-0173(99)00045-4).
- 485 (43) Tartar, J. L.; Cabrera, D.; Knafo, S.; Thomas, J. D.; Antonio, J.; Peacock, C. A. The “Warrior”
486 COMT Val/Met Genotype Occurs in Greater Frequencies in Mixed Martial Arts Fighters
487 Relative to Controls. *J. Sport. Sci. Med.* **2020**, *19* (1), 38–42.

- 488 (44) Stein, D. J.; Newman, T. K.; Savitz, J.; Ramesar, R. Warriors versus Worriers: The Role of COMT
489 Gene Variants. *CNS Spectr.* **2006**, *11* (10), 745–748.
490 <https://doi.org/10.1017/S1092852900014863>.
- 491 (45) Heffernan, S. M.; Kilduff, L. P.; Erskine, R. M.; Day, S. H.; Stebbings, G. K.; Cook, C. J.; Raleigh,
492 S. M.; Bennett, M. A.; Wang, G.; Collins, M.; Pitsiladis, Y. P.; Williams, A. G. COL5A1 Gene
493 Variants Previously Associated with Reduced Soft Tissue Injury Risk Are Associated with Elite
494 Athlete Status in Rugby. *BMC Genomics* **2017**, *18* (Suppl 8). [https://doi.org/10.1186/s12864-](https://doi.org/10.1186/s12864-017-4187-3)
495 [017-4187-3](https://doi.org/10.1186/s12864-017-4187-3).
- 496 (46) Heffernan, S. M.; Kilduff, L. P.; Day, S. H.; Pitsiladis, Y. P.; Williams, A. G. Genomics in Rugby
497 Union: A Review and Future Prospects. *Eur. J. Sport Sci.* **2015**, *15* (6), 460–468.
498 <https://doi.org/10.1080/17461391.2015.1023222>.
- 499 (47) World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research
500 Involving Human Subjects. *JAMA - J. Am. Med. Assoc.* **2013**, *310* (20), 2191–2194.
501 <https://doi.org/10.1001/jama.2013.281053>.
- 502 (48) Heffernan, S. M.; Kilduff, L. P.; Erskine, R. M.; Day, S. H.; McPhee, J. S.; McMahon, G. E.;
503 Stebbings, G. K.; Neale, J. P. H.; Lockey, S. J.; Ribbans, W. J.; Cook, C. J.; Vance, B.; Raleigh, S.
504 M.; Roberts, C.; Bennett, M. A.; Wang, G.; Collins, M.; Pitsiladis, Y. P.; Williams, A. G.
505 Association of ACTN3 R577X but Not ACE I/D Gene Variants with Elite Rugby Union Player
506 Status and Playing Position. *Physiol. Genomics* **2016**, *48* (3), 196–201.
507 <https://doi.org/10.1152/physiolgenomics.00107.2015>.
- 508 (49) Heffernan, S. M.; Stebbings, G. K.; Kilduff, L. P.; Erskine, R. M.; Day, S. H.; Morse, C. I.;
509 McPhee, J. S.; Cook, C. J.; Vance, B.; Ribbans, W. J.; Raleigh, S. M.; Roberts, C.; Bennett, M. A.;
510 Wang, G.; Collins, M.; Pitsiladis, Y. P.; Williams, A. G. Fat Mass and Obesity Associated (FTO)
511 Gene Influences Skeletal Muscle Phenotypes in Non-Resistance Trained Males and Elite
512 Rugby Playing Position. *BMC Genet.* **2017**, *18* (1). [https://doi.org/10.1186/s12863-017-0470-](https://doi.org/10.1186/s12863-017-0470-1)
513 [1](https://doi.org/10.1186/s12863-017-0470-1).
- 514 (50) Lahiri, D. K.; Numberger, J. I. A Rapid Non-Enzymatic Method for the Preparation of HMW
515 DNA from Blood for RFLP Studies. *Nucleic Acids Res.* **1991**, *19* (19), 5444.
516 <https://doi.org/10.1093/nar/19.19.5444>.
- 517 (51) Hixson, J. E.; Vernier, D. T. Restriction Isotyping of Human Apolipoprotein E by Gene
518 Amplification and Cleavage with HhaI. *J. Lipid Res.* **1990**, *31*, 545–548.

- 519 (52) Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful
520 Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B*
521 *(Methodological)*. WileyRoyal Statistical Society 1995, pp 289–300.
522 <https://doi.org/10.2307/2346101>.
- 523 (53) Winkler, E. A.; Yue, J. K.; McAllister, T. W.; Temkin, N. R.; Oh, S. S.; Burchard, E. G.; Hu, D.;
524 Ferguson, A. R.; Lingsma, H. F.; Burke, J. F.; Sorani, M. D.; Rosand, J.; Yuh, E. L.; Barber, J.;
525 Tarapore, P. E.; Gardner, R. C.; Sharma, S.; Satris, G. G.; Eng, C.; Puccio, A. M.; Wang, K. K. W.;
526 Mukherjee, P.; Valadka, A. B.; Okonkwo, D. O.; Diaz-Arrastia, R.; Manley, G. T. COMT Val 158
527 Met Polymorphism Is Associated with Nonverbal Cognition Following Mild Traumatic Brain
528 Injury. *Neurogenetics* **2016**, *17* (1), 31–41. <https://doi.org/10.1007/s10048-015-0467-8>.
- 529 (54) Tunbridge, E. M.; Harrison, P. J.; Weinberger, D. R. Catechol-o-Methyltransferase, Cognition,
530 and Psychosis: Val158Met and Beyond. *Biological Psychiatry*. Biol Psychiatry July 15, 2006, pp
531 141–151. <https://doi.org/10.1016/j.biopsych.2005.10.024>.
- 532 (55) Chen, J.; Lipska, B.; Halim, N.; Ma, Q.; Matsumoto, M.; Melhem, S.; Kolachana, B.; Hyde, T.;
533 Herman, M.; Apud, J.; Egan, M.; Kleinman, J.; Weinberger, D. Functional Analysis of Genetic
534 Variation in Catechol-O-Methyltransferase (COMT): Effects on mRNA, Protein, and Enzyme
535 Activity in Postmortem Human Brain. *Am. J. Hum. Genet.* **2004**, *75* (5), 807–821.
536 <https://doi.org/10.1086/425589>.
- 537 (56) Riba, J.; Krämer, U.; Heldmann, M.; Richter, S.; Münte, T. Dopamine Agonist Increases Risk
538 Taking but Blunts Reward-Related Brain Activity. *PLoS One* **2008**, *3* (6), e2479.
539 <https://doi.org/10.1371/journal.pone.0002479>.
- 540 (57) Dalley, J.; Roiser, J. Dopamine, Serotonin and Impulsivity. *Neuroscience* **2012**, *215*, 42–58.
541 <https://doi.org/10.1016/J.NEUROSCIENCE.2012.03.065>.
- 542 (58) Serrano, J. M.; Banks, J. B.; Fagan, T. J.; Tartar, J. L. The Influence of Val158Met COMT on
543 Physiological Stress Responsivity. *Stress* **2019**, *22* (2), 276–279.
544 <https://doi.org/10.1080/10253890.2018.1553949>.
- 545 (59) Kilford, E. J.; Dumontheil, I.; Wood, N. W.; Blakemore, S.-J. Influence of COMT Genotype and
546 Affective Distractors on the Processing of Self-Generated Thought. *Soc. Cogn. Affect.*
547 *Neurosci.* **2015**, *10* (6), 777–782. <https://doi.org/10.1093/scan/nsu118>.
- 548 (60) Soeiro-De-Souza, M. G.; Bio, D. S.; David, D. P.; Missio, G.; Lima, B.; Fernandes, F.; Machado-
549 Vieira, R.; Moreno, R. A. Gender Effects of the COMT Val 158 Met Genotype on Verbal

550 Fluency in Healthy Adults. *Mol. Med. Rep.* **2013**, *8* (3), 837–844.
551 <https://doi.org/10.3892/MMR.2013.1564>.

552 (61) Olsson, C. A.; Anney, R. J. L.; Lotfi-Miri, M.; Byrnes, G. B.; Williamson, R.; Patton, G. C.
553 Association between the COMT Val158Met Polymorphism and Propensity to Anxiety in an
554 Australian Population-Based Longitudinal Study of Adolescent Health. *Psychiatr. Genet.* **2005**,
555 *15* (2), 109–115. <https://doi.org/10.1097/00041444-200506000-00007>.

556 (62) Diatchenko, L.; Slade, G. D.; Nackley, A. G.; Bhalang, K.; Sigurdsson, A.; Belfer, I.; Goldman, D.;
557 Xu, K.; Shabalina, S. A.; Shagin, D.; Max, M. B.; Makarov, S. S.; Maixner, W. Genetic Basis for
558 Individual Variations in Pain Perception and the Development of a Chronic Pain Condition.
559 *Hum. Mol. Genet.* **2005**, *14* (1), 135–143. <https://doi.org/10.1093/hmg/ddi013>.

560 (63) Korczeniewska, O. A.; Kuo, F.; Huang, C. Y.; Nasri-Heir, C.; Khan, J.; Benoliel, R.; Hirschberg, C.;
561 Eliav, E.; Diehl, S. R. Genetic Variation in Catechol-O-Methyltransferase Is Associated with
562 Individual Differences in Conditioned Pain Modulation in Healthy Subjects. *J. Gene Med.*
563 **2021**, *23* (11). <https://doi.org/10.1002/JGM.3374>.

564 (64) Lin, W.; Farella, M.; Antoun, J. S.; Topless, R. K.; Merriman, T. R.; Michelotti, A. Factors
565 Associated with Orthodontic Pain. *J. Oral Rehabil.* **2021**, *48* (10), 1135–1143.
566 <https://doi.org/10.1111/JOOR.13227>.

567 (65) Crews, K. R.; Monte, A. A.; Huddart, R.; Caudle, K. E.; Kharasch, E. D.; Gaedigk, A.;
568 Dunnenberger, H. M.; Leeder, J. S.; Callaghan, J. T.; Samer, C. F.; Klein, T. E.; Haidar, C. E.; Van
569 Driest, S. L.; Ruano, G.; Sangkuhl, K.; Cavallari, L. H.; Müller, D. J.; Prows, C. A.; Nagy, M.;
570 Somogyi, A. A.; Skaar, T. C. Clinical Pharmacogenetics Implementation Consortium Guideline
571 for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. *Clin. Pharmacol. Ther.*
572 **2021**, *110* (4), 888–896. <https://doi.org/10.1002/CPT.2149>.

573 (66) Cosgrave, M.; Williams, S. The Epidemiology of Concussion in Professional Rugby Union in
574 Ireland. *Phys. Ther. Sport* **2019**, *35*, 99–105. <https://doi.org/10.1016/j.ptsp.2018.11.010>.

575 (67) Hinton-Bayre, A. D.; Geffen, G.; Friis, P. Presentation and Mechanisms of Concussion in
576 Professional Rugby League Football. *J. Sci. Med. Sport* **2004**, *7* (3), 400–404.

577